Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Duchenne Muscular Dystrophy (DMD): early-phase trial registry
3 of 4 indexed Duchenne Muscular Dystrophy (DMD) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Duchenne Muscular Dystrophy (DMD): 4 US clinical trials tracked, 3 recruiting.
Duchenne Muscular Dystrophy (DMD) is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Dyne Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition duchenne-muscular-dystrophy-dmd
OPEN 3 | RECR 75% | LATE 0 | EARLY 1 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Duchenne Muscular Dystrophy (DMD) lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Duchenne Muscular Dystrophy (DMD) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Duchenne Muscular Dystrophy (DMD) is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders
Columbia University
NCT06839469
DMD Voice: Qualitative Interviews With Patients and Caregivers
Red Nucleus Enterprise Solutions
NCT06925269
Urinary Titin Biomarker in DMD
Children's Hospital of Philadelphia
NCT07332013
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Dyne Therapeutics
NCT05524883
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Duchenne Muscular Dystrophy (DMD) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Duchenne Muscular Dystrophy (DMD) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Duchenne Muscular Dystrophy (DMD) page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Duchenne Muscular Dystrophy (DMD) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Dyne Therapeutics sponsors the most Duchenne Muscular Dystrophy (DMD) trials on record, review their full trial history before evaluating a specific study. See Dyne Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Duchenne Muscular Dystrophy (DMD) condition card totals 4 registered trials; most-linked intervention DYNE-251; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.